Feb 18 (Reuters) - Biogen Inc BIIB.O:
BIOGEN AND STOKE THERAPEUTICS ENTER INTO COLLABORATION TO DEVELOP AND COMMERCIALIZE ZOREVUNERSEN FOR THE TREATMENT OF DRAVET SYNDROME, A RARE GENETIC EPILEPSY ASSOCIATED WITH REFRACTORY SEIZURES AND NEURODEVELOPMENTAL IMPAIRMENTS
BIOGEN INC - PHASE 3 STUDY OF ZOREVUNERSEN TO INITIATE IN Q2 2025
BIOGEN INC - STOKE RETAINS EXCLUSIVE RIGHTS FOR ZOREVUNERSEN IN US, CANADA, MEXICO; BIOGEN GETS REST OF WORLD
Source text: ID:nBwbh3DmPa
Further company coverage: BIIB.O
((reuters.briefs@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。